Indexing
CÁC SỐ TỪ 2011-2023
Tạp chí Y Dược Học
Abstract
ABSTRACT
Background/Objectives: Understanding the roles of p53 and Bcl-2 in breast cancer carries significant clinical implications, as these markers may serve as valuable prognostic indicators for therapeutic management. Objectives: 1/To characterize the immunohistochemical expression patterns of p53 and Bcl-2 in breast adenocarcinoma. 2/ To investigate the correlation between the expression of these markers and molecular subtypes of breast adenocarcinoma.
Methods: This study was conducted on tissue specimens from 63 invasive breast cancer patients who underwent examination and treatment at Hue University of Medicine and Pharmacy Hospital between November 2024 and April 2026. Breast cancer tissue samples were subjected to immunohistochemical staining for molecular subtyping using four markers (ER, PR, HER2, and Ki-67), in addition to the evaluation of p53 and Bcl2 expression.
Results: The positivity rates for p53 and Bcl-2 were 31.7% and 53.8%, respectively. The most prevalent combined phenotype was p53(-)/Bcl-2(+) (38.5%). Regarding molecular subtypes, the Luminal B subtype predominated (46.0%), followed by Luminal A (25.4%), HER2-enriched (19.0%), and Triple-negative (9.5%). The p53(-)
/Bcl-2(+) phenotype was most frequent in the Luminal A (71.4%) and Triple-negative (60.0%) subtypes. Conversely, the p53(+)/Bcl-2(-) phenotype reached its highest concentration in the HER2-enriched group (54.5%).
Conclusions: p53 overexpression and loss of Bcl-2 expression are associated with poor-prognosis molecular subtypes (HER2-enriched), whereas p53 negativity and Bcl-2 expression are primarily concentrated in favorable-prognosis subtypes (Luminal A).
Keywords: Breast cancer, molecular subtypes, p53, Bcl2
| Published | 2026-10-14 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 6 (2026) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2026.6.1516 | |
| Keywords |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Hue Journal of Medicine and Pharmacy
Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024. 74(3): p. 229-263.
Linjawi, A., et al., Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg, 2004. 198(1): p. 83-90.
Eom, Y.H., et al., BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer. J Breast Cancer, 2016. 19(3): p. 252-260.
Hwang, K.-T., et al., Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer. J Breast Cancer, 2017. 20(1): p. 54-64.
Nguyen, V.C., et al., Application of St Gallen Categories in Predicting Survival for Patients With Breast Cancer in Vietnam. Cancer Control, 2019. 26(1): p. 1073274819862794.
Trần, M.H. and T.H.T. Đinh, Tỉ lệ các type phân tử ung thư biểu mô tuyến vú ở nữ giới điều trị tại bệnh viện đa khoa tỉnh thái bình. Tạp chí Y học Việt Nam, 2024. 541(2).
Dajti, G., et al., Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors. Oncologist, 2024. 29(5): p. 384-391.
Nugrohowati, N., M.E. Setyowati, and T. Kusuma, Association between p53 Status and Breast Cancer Molecular Subtypes in the Academic Hospital of Universitas Gadjah Mada. eJournal Kedokteran Indonesia, 2025. 13(1): p. 59.
Gogoi, S., Das, B., Borgohain, M., Gogoi, G., Das, J. , Ki67 and P53 expression in breast cancer and their correlation with clinicopathological parameters. Indian Journal of Pathology and Oncology, (2021). 8(4): p. 478-484.
Hermansyah, D., et al., Intercontinental Comparison of Immunohistochemical Subtypes Among Individuals With Breast Cancer in South-East Asia and South America: A Scoping Systematic Review and Meta-Analysis of Observational Studies. World J Oncol, 2024. 15(3): p. 355-371.
Van Nguyen, C., et al., Combined p53 and Bcl2 Immunophenotypes in Prognosis of Vietnamese Invasive Breast Carcinoma: A Single Institutional Retrospective Analysis. Technol Cancer Res Treat, 2020. 19: p. 1533033820983081.
Marvalim, C., A. Datta, and S.C. Lee, Role of p53 in breast cancer progression: An insight into p53 targeted therapy. Theranostics, 2023. 13(4): p. 1421-1442.
Bealy, M.A., et al., Patterns of Immunohistochemical Expression of P53, BCL2, PTEN, and HER2/neu Tumor Markers in Specific Breast Cancer Lesions. Evid Based Complement Alternat Med, 2022: p. 2026284.
Jindal, B., Thakral, R. K., Mohan, A., Ansari, V., Sharma, V. K. , Role of p53 as a prognostic marker in breast carcinoma and its correlation with tumor size, tumor grade and lymph node metastasis. ndian Journal of Pathology and Oncology, 2020. 7(3): p. 378-383.
Rolland, P., et al., The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. International journal of cancer, 2007. 120(6): p. 1311-1317.
Malamou-Mitsi, V., et al., Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol, 2006. 17(10): p. 1504-11.
Silwal-Pandit, L., et al., TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res, 2014. 20(13): p. 3569-80.
Yamashita, H., et al., Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res, 2004. 6(1): p. R24-30.